- Home
- ATHA vs ISPC Comparison
ATHA vs ISPC Comparison
Compare ATHA & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- ISPC
- Stock Information
- Founded
- ATHA 2011
- ISPC 2009
- Country
- ATHA United States
- ISPC United States
- Employees
- ATHA N/A
- ISPC N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- ISPC Precision Instruments
- Sector
- ATHA Health Care
- ISPC Health Care
- Exchange
- ATHA Nasdaq
- ISPC Nasdaq
- Market Cap
- ATHA 14.8M
- ISPC 13.9M
- IPO Year
- ATHA 2020
- ISPC 2021
- Fundamental
- Price
- ATHA $3.82
- ISPC $0.83
- Analyst Decision
- ATHA
- ISPC
- Analyst Count
- ATHA 0
- ISPC 0
- Target Price
- ATHA N/A
- ISPC N/A
- AVG Volume (30 Days)
- ATHA 48.3K
- ISPC 1.2M
- Earning Date
- ATHA 11-06-2025
- ISPC 11-06-2025
- Dividend Yield
- ATHA N/A
- ISPC N/A
- EPS Growth
- ATHA N/A
- ISPC N/A
- EPS
- ATHA N/A
- ISPC N/A
- Revenue
- ATHA N/A
- ISPC $5,908,088.00
- Revenue This Year
- ATHA N/A
- ISPC $35.93
- Revenue Next Year
- ATHA N/A
- ISPC N/A
- P/E Ratio
- ATHA N/A
- ISPC N/A
- Revenue Growth
- ATHA N/A
- ISPC N/A
- 52 Week Low
- ATHA $2.20
- ISPC $0.64
- 52 Week High
- ATHA $8.26
- ISPC $8.30
- Technical
- Relative Strength Index (RSI)
- ATHA 63.70
- ISPC 38.32
- Support Level
- ATHA $3.61
- ISPC $0.78
- Resistance Level
- ATHA $4.04
- ISPC $1.33
- Average True Range (ATR)
- ATHA 0.25
- ISPC 0.11
- MACD
- ATHA -0.16
- ISPC -0.05
- Stochastic Oscillator
- ATHA 20.92
- ISPC 7.99
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.